Polymorphisms in innate immunity genes and patients response to dendritic cell-based HIV immuno-treatment

Ludovica Segat, Lucas A C Brandão, Rafael L. Guimarães, Alessandra Pontillo, Emmanouil Athanasakis, Rafael Martins de Oliveira, Luiz C. Arraes, Josè Luiz de Lima Filho, Sergio Crovella

Research output: Contribution to journalArticle

Abstract

Dendritic cells (DCs)-based vaccine was demonstrated to increase HIV specific cellular immune response; however, in some HIV-infected patients, the response to the vaccine resulted to be not effective. In order to understand if the outcome of the vaccination may be influenced by the host's genome and natural immunity, we studied the innate immune genome of HIV-infected patients previously vaccinated with DCs. We identified 15 SNPs potentially associated with the response to the immuno-treatment and two SNPs significantly associated with the modulation of the response to the DC vaccine: MBL2 rs10824792 and NOS1 rs693534. These two SNPs were also studied in different ethnic groups (Brazilians, African and Caucasian) of HIV-infected, exposed uninfected and unexposed uninfected subjects. The HIV positive Caucasian patients were also characterized by different disease progressions. Our findings suggest that, independently and/or in addition to other variables, the host's genome could significantly contribute to the modulation of the response to the DC vaccine.

Original languageEnglish
Pages (from-to)2201-2206
Number of pages6
JournalVaccine
Volume28
Issue number10
DOIs
Publication statusPublished - Mar 2 2010

Fingerprint

dendritic cells
Innate Immunity
Dendritic Cells
HIV
genetic polymorphism
vaccines
Vaccines
Single Nucleotide Polymorphism
Genes
genome
Genome
genes
Therapeutics
nationalities and ethnic groups
disease course
cell-mediated immunity
Ethnic Groups
Cellular Immunity
vaccination
Disease Progression

Keywords

  • Dendritic cell immunotherapy
  • HIV infection
  • Innate immunity

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Polymorphisms in innate immunity genes and patients response to dendritic cell-based HIV immuno-treatment. / Segat, Ludovica; Brandão, Lucas A C; Guimarães, Rafael L.; Pontillo, Alessandra; Athanasakis, Emmanouil; de Oliveira, Rafael Martins; Arraes, Luiz C.; de Lima Filho, Josè Luiz; Crovella, Sergio.

In: Vaccine, Vol. 28, No. 10, 02.03.2010, p. 2201-2206.

Research output: Contribution to journalArticle

Segat, L, Brandão, LAC, Guimarães, RL, Pontillo, A, Athanasakis, E, de Oliveira, RM, Arraes, LC, de Lima Filho, JL & Crovella, S 2010, 'Polymorphisms in innate immunity genes and patients response to dendritic cell-based HIV immuno-treatment', Vaccine, vol. 28, no. 10, pp. 2201-2206. https://doi.org/10.1016/j.vaccine.2009.12.056
Segat L, Brandão LAC, Guimarães RL, Pontillo A, Athanasakis E, de Oliveira RM et al. Polymorphisms in innate immunity genes and patients response to dendritic cell-based HIV immuno-treatment. Vaccine. 2010 Mar 2;28(10):2201-2206. https://doi.org/10.1016/j.vaccine.2009.12.056
Segat, Ludovica ; Brandão, Lucas A C ; Guimarães, Rafael L. ; Pontillo, Alessandra ; Athanasakis, Emmanouil ; de Oliveira, Rafael Martins ; Arraes, Luiz C. ; de Lima Filho, Josè Luiz ; Crovella, Sergio. / Polymorphisms in innate immunity genes and patients response to dendritic cell-based HIV immuno-treatment. In: Vaccine. 2010 ; Vol. 28, No. 10. pp. 2201-2206.
@article{ee00e5228195441fbb271d4c90ba6039,
title = "Polymorphisms in innate immunity genes and patients response to dendritic cell-based HIV immuno-treatment",
abstract = "Dendritic cells (DCs)-based vaccine was demonstrated to increase HIV specific cellular immune response; however, in some HIV-infected patients, the response to the vaccine resulted to be not effective. In order to understand if the outcome of the vaccination may be influenced by the host's genome and natural immunity, we studied the innate immune genome of HIV-infected patients previously vaccinated with DCs. We identified 15 SNPs potentially associated with the response to the immuno-treatment and two SNPs significantly associated with the modulation of the response to the DC vaccine: MBL2 rs10824792 and NOS1 rs693534. These two SNPs were also studied in different ethnic groups (Brazilians, African and Caucasian) of HIV-infected, exposed uninfected and unexposed uninfected subjects. The HIV positive Caucasian patients were also characterized by different disease progressions. Our findings suggest that, independently and/or in addition to other variables, the host's genome could significantly contribute to the modulation of the response to the DC vaccine.",
keywords = "Dendritic cell immunotherapy, HIV infection, Innate immunity",
author = "Ludovica Segat and Brand{\~a}o, {Lucas A C} and Guimar{\~a}es, {Rafael L.} and Alessandra Pontillo and Emmanouil Athanasakis and {de Oliveira}, {Rafael Martins} and Arraes, {Luiz C.} and {de Lima Filho}, {Jos{\`e} Luiz} and Sergio Crovella",
year = "2010",
month = "3",
day = "2",
doi = "10.1016/j.vaccine.2009.12.056",
language = "English",
volume = "28",
pages = "2201--2206",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "10",

}

TY - JOUR

T1 - Polymorphisms in innate immunity genes and patients response to dendritic cell-based HIV immuno-treatment

AU - Segat, Ludovica

AU - Brandão, Lucas A C

AU - Guimarães, Rafael L.

AU - Pontillo, Alessandra

AU - Athanasakis, Emmanouil

AU - de Oliveira, Rafael Martins

AU - Arraes, Luiz C.

AU - de Lima Filho, Josè Luiz

AU - Crovella, Sergio

PY - 2010/3/2

Y1 - 2010/3/2

N2 - Dendritic cells (DCs)-based vaccine was demonstrated to increase HIV specific cellular immune response; however, in some HIV-infected patients, the response to the vaccine resulted to be not effective. In order to understand if the outcome of the vaccination may be influenced by the host's genome and natural immunity, we studied the innate immune genome of HIV-infected patients previously vaccinated with DCs. We identified 15 SNPs potentially associated with the response to the immuno-treatment and two SNPs significantly associated with the modulation of the response to the DC vaccine: MBL2 rs10824792 and NOS1 rs693534. These two SNPs were also studied in different ethnic groups (Brazilians, African and Caucasian) of HIV-infected, exposed uninfected and unexposed uninfected subjects. The HIV positive Caucasian patients were also characterized by different disease progressions. Our findings suggest that, independently and/or in addition to other variables, the host's genome could significantly contribute to the modulation of the response to the DC vaccine.

AB - Dendritic cells (DCs)-based vaccine was demonstrated to increase HIV specific cellular immune response; however, in some HIV-infected patients, the response to the vaccine resulted to be not effective. In order to understand if the outcome of the vaccination may be influenced by the host's genome and natural immunity, we studied the innate immune genome of HIV-infected patients previously vaccinated with DCs. We identified 15 SNPs potentially associated with the response to the immuno-treatment and two SNPs significantly associated with the modulation of the response to the DC vaccine: MBL2 rs10824792 and NOS1 rs693534. These two SNPs were also studied in different ethnic groups (Brazilians, African and Caucasian) of HIV-infected, exposed uninfected and unexposed uninfected subjects. The HIV positive Caucasian patients were also characterized by different disease progressions. Our findings suggest that, independently and/or in addition to other variables, the host's genome could significantly contribute to the modulation of the response to the DC vaccine.

KW - Dendritic cell immunotherapy

KW - HIV infection

KW - Innate immunity

UR - http://www.scopus.com/inward/record.url?scp=77049123430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77049123430&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.12.056

DO - 10.1016/j.vaccine.2009.12.056

M3 - Article

C2 - 20056178

AN - SCOPUS:77049123430

VL - 28

SP - 2201

EP - 2206

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 10

ER -